Predictive Value of Two Polymorphisms of ERCC2, rs13181 and rs1799793, in Clinical Outcomes of Chemotherapy in Gastric Cancer Patients: A Meta-Analysis

Table 5

Association between the ERCC2 rs13181 polymorphism and overall survival of chemotherapy in gastric cancer patients.

Study	Year	Country	Outcomes	ERCC2 rs13181				ERCC2 rs1799793
				AA	AC	CC	AC + CC	GG	GA	AA	GA + AA
Zheng	2016	China	OS	1.0 (ref.)	1.10 (0.56–2.15)	1.37 (0.46–3.80)	—	1.0 (ref.)	1.12 (0.56–2.22)	1.38 (0.46–3.80)	—
Mo	2015	China	OS	1.0 (ref.)	1.14 (0.58–2.28)	1.35 (0.48–3.53)	1.20 (0.64–2.25)	1.0 (ref.)	1.12 (0.57–2.20)	1.93 (0.58–6.00)	1.25 (0.66–2.34)
Yu	2015	China	OS	1.0 (ref.)	—	—	1.57 (0.93–2.65)	1.0 (ref.)	—	—	1.78 (1.13–2.81)
Zhong	2015	China	OS	—	—	—	—	1.00 (ref)	1.15 (0.63–2.10)	1.76 (0.53–5.38)	1.23 (0.69–2.18)
Ding	2015	China	OS	1.0 (ref.)	—	—	1.05 (0.68–1.62)	1.0 (ref.)	—	—	1.97 (1.28–3.03)
Liu	2015	China	OS	1.0 (ref.)	—	—	1.12 (0.44–2.88)	1.0 (ref.)	2.12 (0.89–5.08)	—	—
Xue	2015	China	OS	1.0 (ref.)	0.66 (0.39–1.11)	0.44 (0.20–0.91)	—	1.0 (ref.)	0.82 (0.49–1.38)	0.75 (0.31–1.71)	—
Yu	2015	China	OS	1.0 (ref.)	1.31 (0.73–2.36)	1.75 (0.57–5.40)	—	1.0 (ref.)	1.52 (0.75–2.86)	3.86 (1.36–12.23)	—
Keam	2008	South Korea	OS	1.0 (ref.)	—	—	0.49 (0.17–1.37)	1.0 (ref.)	0.80 (0.28–2.26)	—	—

OS: overall survival.